Mr. Axe is a Managing Director at NovaQuest Capital Management and has 20 years of extensive experience in the biomedical industry across pharmaceuticals, animal health, and medical devices. He is primarily responsible for leading the animal health strategy through portfolio management, sourcing, due diligence and transaction structuring of investment opportunities.
Mr. Axe joined NovaQuest Capital after 15 years at Eli Lilly and Co., where he held various positions including R&D Analytical Chemist, Project Management Advisor, Due Diligence Advisor, and most recently Due Diligence Advisor for Elanco Business Development. There he was responsible for and led the corporate and scientific and technical due diligence evaluations associated with global transactions for in-licensing, out-licensing, divestitures, merger and acquisitions, as well as alternative deal structures. His experience spans all therapeutic areas, phases of development, animal segments, and geographies.